Access leading, evidence-based scientific and market information on drugs in commercial development worldwide. Drug and cell-based products are tracked across all therapeutic areas and throughout the entire development process, from discovery to launch.

Profiles include:

• Key development milestones
• Development status and history
• Drug properties
• Chemical synopses
• Pharmacokinetics data
• Pharmacodynamics data
• Company agreements
• Trial landscape and details
• Related safety reports
• Patent information
• Related drugs
• Drug limitations
• Immunogenicity

Quickly identify the clinical trials being performed to advance these drugs through international regulatory pathways, with coverage of both international and observational trials.

Profiles include:

• Phase of trial and current status
• Trial purpose, focus and design
• Primary and other endpoints
• Diseases and subjects treated
• Inclusion and exclusion criteria
• Trial identifiers
• Organizations involved
• Initiation, completion and end dates
• Interventions
• Study center and investigator details
• Trial history
• Outcomes and results
• Related authors

AdisInsight Safety delivers comprehensive, high-quality safety intelligence by leveraging a cutting-edge, automated content acquisition process that blends advanced AI/ML technologies with expert human validation. This future-ready approach minimizes human error, ensures adaptability to evolving regulatory requirements, and enables the integration of diverse data sources, including local literature. Users benefit from expanded access to safety-related content that is clearly categorized and easily filterable—making it simple to find the precise information needed for informed decision-making.

• Faster access to safety-relevant articles: By removing the delay caused by traditional indexing of major literature databases, you gain faster access to safety-relevant articles—often weeks or months earlier than before.
• Find the safety insights that matter most: Keywords extracted from the article are automatically normalized to the Adis thesaurus, helping you quickly find and process the most pertinent safety information.
• More efficient triage: Our new process performs a first-pass triage to assess the likelihood of an article being an Individual Case Safety Report (ICSR), helping you prioritize and triage more effectively on your end. This means less time spent sorting and more time acting on the most relevant safety information.
• More Safety Content: Enhanced coverage to include all articles that contain a drug and either an adverse event or a special situation supports broader use cases, including signal detection, aggregate reporting, and more.
• Higher Quality: With complete control over the data acquisition pipeline, we ensure consistent, high-quality safety content from source to delivery. This end-to-end oversight minimizes gaps, reduces variability, and enhances the reliability of the information you receive—giving you greater confidence in your safety assessments and reporting.

To support your pharmacovigilance and safety monitoring needs, AdisInsight classifies safety-related content into the following categories:

• ADR Category 1: The source material explicitly or strongly suggests a drug–adverse reaction association in at least one identifiable patient, with a specific drug and adverse event mentioned together and a plausible causal relationship implied.
• ADR Category 2: The source material suggests a possible drug–event association or safety concern in an individual or group of patients but lacks sufficient details. The supporting evidence may be indirect, preliminary, or ambiguous.
• ADR Category 3: The source material offers safety-relevant context without identifying a specific drug–event pair. It may discuss risk factors, pharmacological mechanisms, class-wide warnings, or general safety considerations.
• Special Situation: Source material without an ADR fitting an AdisInsight category but does contain use of a medicinal product during pregnancy or breastfeeding, or reports of off-label use, overdose, abuse, misuse, medication error, occupational exposure, or lack of therapeutic efficacy.
• News: Selected and summarized by Adis Editors from a variety of sources, including published adverse drug reaction case reports, regulatory agencies, scientific meetings, and media releases.

Review concise summaries of purchases and acquisitions, joint ventures, and agreements for licensing, R&D, development, manufacturing, distribution and marketing with deal values given, where available. AdisInsight can help you to keep up with the ever-changing landscape of drug development, to identify opportunities for investment, business development and collaboration, and benchmark relative deal values and terms for your own technologies.

Profiles include:

• Type of agreement
• Date of agreement
• Organizations involved
• Drugs involved
• Indications involved
• Summary of the deal
• Deal value

Patents is an extension of Drugs providing key information about the global parents and market exclusivities protecting a specific drug. For an AdisInsight Drug profile there is a corresponding Drug Patent Profile that presents the global patents and market exclusivities that are protecting that drug. Patent information is presented in summary tables to facilitate quick and easy understanding of key patent information impacting a drug landscape and determining the timing of generic entry.

• Drug name
• Country
• Patent number
• Claim type
• Patent title
• Filing date
• Loss of patent date
• Brand name
• BLA / NDA / ANDA
• Patent applicant
• Source